MedPath

Clinical Trial News

Summit Therapeutics' Phase III Trial Bests Merck's Keytruda in Lung Cancer

  • Summit Therapeutics' SMT-i100 demonstrated superior efficacy compared to Keytruda in a Phase III trial for non-small cell lung cancer (NSCLC).
  • The study highlighted SMT-i100's potential as a novel therapeutic option, particularly in patients with PD-L1 negative or low expressing tumors.
  • These results suggest a significant advancement in lung cancer treatment, offering hope for improved outcomes in a challenging patient population.

Novel Therapies and Lifestyle Interventions Show Promise in Hypertension Management

  • Recent trials highlight the potential of salt substitution and restriction in lowering blood pressure, particularly in elderly care facilities, showcasing significant cardiovascular benefits.
  • Emerging drug therapies, including aldosterone synthase inhibitors like baxdrostat and lorundrostat, demonstrate efficacy in treatment-resistant hypertension by targeting aldosterone production.
  • Bariatric surgery has shown sustained reductions in blood pressure over five years in obese patients with hypertension, suggesting a durable impact on cardiovascular health.
  • SGLT2 inhibitors, initially for diabetes, are recognized for their beneficial effects on blood pressure regulation, offering a dual-action approach for patients with both conditions.

Adaptive Trial Aims to Break Impasse in Traumatic Brain Injury Treatment

  • A new clinical trial is launched across 18 trauma centers to evaluate existing drugs for treating moderate to mild traumatic brain injury (TBI).
  • The adaptive platform trial design allows simultaneous testing of multiple drugs and the addition/removal of therapies based on efficacy.
  • The trial leverages recent biomarker and CT scan research to improve patient selection and monitor treatment progress.
  • Funded by the Department of Defense, the study addresses the urgent need for effective TBI treatments, which affects millions.

Rintatolimod and Durvalumab Combination Shows Promise in Late-Stage Pancreatic Cancer

  • Preliminary data from the DURIPANC trial indicates that rintatolimod plus durvalumab demonstrates early disease control in late-stage pancreatic cancer.
  • Two of three patients in the first dose cohort maintained stable disease at 6 months, with ongoing treatment and assessment.
  • The combination therapy was generally well-tolerated, with no severe adverse effects observed in the first cohort.
  • Improvements in quality of life were noted, correlating with stable disease, offering hope for patients with limited treatment options.

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

NCT05927142RecruitingPhase 1
Joachim Aerts, MD PhD
Posted 1/9/2024

UNLV and Global Alzheimer's Platform Foundation Partner to Advance Alzheimer's Research

  • UNLV and the Global Alzheimer’s Platform Foundation (GAP) are collaborating to accelerate the development of new diagnostic tests and biomarkers for Alzheimer’s and other CNS diseases.
  • The partnership aims to expand access to clinical trials in Southern Nevada, focusing on including participants from diverse communities.
  • The collaboration will leverage UNLV's Pam Quirk Brain Health Biomarker Laboratory and GAP's biomarker datasets to enhance research capabilities.
  • UNLV students will gain opportunities in brain science and clinical research, with plans for an annual conference on biomarker technologies.

VITdALIZE-KIDS Trial Assesses Vitamin D Supplementation Impact on Pediatric ICU Patients' Quality of Life

  • The VITdALIZE-KIDS trial is a phase III, multicenter, randomized, double-blind study evaluating high-dose vitamin D supplementation in critically ill children with vitamin D deficiency.
  • The primary outcome is health-related quality of life (HRQL) measured by the PedsQL™ scale at 28 days post-intervention, with secondary outcomes including hospital length of stay and adverse events.
  • The trial aims to enroll 766 patients across 11 Canadian PICUs, randomizing them to either a high-dose cholecalciferol bolus or a placebo, with a metabolomics sub-study planned for a subset.
  • Interim analyses are scheduled to assess efficacy and safety, with a DSMB providing oversight and the potential for early termination based on futility or safety concerns.

Rapid Normalization of Vitamin D Deficiency in PICU

NCT03742505CompletedPhase 3
Children's Hospital of Eastern Ontario
Posted 6/17/2019

Ryvu Therapeutics Doses First Patient in Phase II REMARK Trial of RVU120 for Lower-Risk MDS

  • Ryvu Therapeutics has dosed the first patient in the Phase II REMARK trial, evaluating RVU120 for anemia in lower-risk myelodysplastic syndromes (LR-MDS).
  • The REMARK study, an investigator-initiated trial through the EMSCO network, will enroll approximately 40 patients across 25 global clinical sites.
  • RVU120, a novel CDK8/19 inhibitor, is being explored as a monotherapy for LR-MDS patients who have exhausted other treatment options.
  • The trial's primary goal is to achieve hematologic improvement, with secondary endpoints including transfusion independence and improved hemoglobin levels.

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

NCT06268574Active, Not RecruitingPhase 2
Ryvu Therapeutics SA
Posted 1/23/2024

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

NCT06397313RecruitingPhase 2
Ryvu Therapeutics SA
Posted 9/19/2024

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Active, Not RecruitingPhase 2
GCP-Service International West GmbH
Posted 9/10/2024

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263RecruitingPhase 2
Ryvu Therapeutics SA
Posted 1/5/2024

Mpox Vaccine Shows Safety and Robust Immune Response in Adolescents

  • A NIH-funded clinical trial found the MVA-BN mpox vaccine safe and effective in adolescents aged 12-17, generating antibody responses similar to those in adults.
  • Interim analysis showed adolescents had higher geometric mean titers (GMT) compared to adults after two doses of the MVA-BN vaccine, indicating a strong immune response.
  • The EMA has recommended extending the use of the Imvanex vaccine to adolescents, based on data showing similar immune responses and safety profiles as in adults.
  • These findings support the use of the MVA-BN vaccine in adolescents, especially in areas with ongoing mpox outbreaks, while further studies in younger children are needed.

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

NCT05512949CompletedPhase 2
National Institute of Allergy and Infectious Diseases (NIAID)
Posted 9/9/2022

SGLT-2 Inhibitors Linked to Reduced Dementia and Parkinson's Risk in Type 2 Diabetes Patients

  • A recent study suggests that SGLT-2 inhibitors, used for type 2 diabetes, are associated with a lower risk of dementia and Parkinson's disease.
  • The research, involving over 220,000 type 2 diabetes patients, found a 35% reduced risk of dementia with SGLT-2 inhibitors compared to DPP-4 inhibitors.
  • SGLT-2 inhibitor use was linked to a 39% lower risk of Alzheimer's and a 52% lower risk of vascular dementia.
  • The study highlights the potential for repurposing existing drugs like SGLT-2 inhibitors to address neurodegenerative diseases.

Pharmacosmos Completes Strategic Acquisition of G1 Therapeutics in Multi-Million Dollar Deal

  • Danish pharmaceutical company Pharmacosmos has finalized its acquisition of US-based G1 Therapeutics, gaining ownership of the cancer drug Cosela in a deal valued at over half a billion kroner.
  • The acquisition represents a significant expansion for Pharmacosmos, traditionally focused on iron deficiency treatments, into the oncology market with an established commercial product.
  • Company executives indicate they will focus on integration over the next six months, with potential for additional acquisitions in the longer term but not immediately.

Trending News

1

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

2 days ago
2

Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results

2 days ago
3

Percheron Therapeutics Acquires Phase II-Ready Anti-VISTA Cancer Immunotherapy HMBD-002 in $290M Deal

2 days ago
4

Galderma Launches Phase II Trials of Nemolizumab for Systemic Sclerosis and Chronic Pruritus of Unknown Origin

3 days ago
5

UCB's Fenfluramine Achieves Positive Phase 3 Results in Ultra-Rare CDKL5 Deficiency Disorder

15 hours ago
6

FDA Approves Streamlined Access for Bristol Myers Squibb CAR T Cell Therapies

15 hours ago
7

China Approves First Once-Daily Nebulized LAMA for COPD, Triggering $7.5M Milestone for Theravance

a day ago
8

ProFound Therapeutics Partners with Novartis in $775M Cardiovascular Drug Discovery Deal

a day ago
9

Lipocine Initiates Phase 3 Trial for Oral Brexanolone in Postpartum Depression

a day ago
10

NHS Delivers First Brain-Infused Gene Therapy for Rare AADC Deficiency, Showing Promising Results in Three-Year-Old Patient

3 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy